IL-2/B7.1 fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: A strategy to generate whole cell vaccines for AML

IL-2/B7.1 fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: A strategy to generate whole cell vaccines for AML

Dades bibliogràfiques
Autors principals:	Chan, L, Hardwick, N, Darling, D, Galea-Lauri, J, Gaken, J, Devereux, S, Kemeny, M, Mufti, G, Farzaneh, F
Format:	Journal article
Publicat:	2004

Ítems similars

IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML.
per: Chan, L, et al.
Publicat: (2005)

Transduction of Primary AML Cells with Lentiviral Vector for In Vitro Study or In Vivo Engraftment
per: Aaron D. Schimmer, et al.
Publicat: (2020-12-01)

Fusagene vectors: A novel strategy for the expression of multiple genes from a single cistron
per: Gaken, J, et al.
Publicat: (1998)

Fusagene vectors: a novel strategy for the expression of multiple genes from a single cistron.
per: Gäken, J, et al.
Publicat: (2000)

Fusagene vectors: a novel strategy for the expression of multiple genes from a single cistron
per: Gaken, J, et al.
Publicat: (2001)

Tumour cells expressing B7.1 costimulatory molecule: Are these better targets for NK cells?
per: GaleaLauri, J, et al.
Publicat: (1996)

Induction of tumour rejection by autologous and allogeneic tumour cells expressing B7.1 and IL-2.
per: Hirst, W, et al.
Publicat: (1996)

Induction of tumour rejection by B7.1 and IL-2 expressing tumour cells
per: Gaken, J, et al.
Publicat: (1997)

Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML
per: Ju Huang, et al.
Publicat: (2016-01-01)

TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
per: Eleonora De Bellis, et al.
Publicat: (2017-07-01)

Monocistronic high titre vectors for targeted expression of multiple therapeutic genes
per: Darling, D, et al.
Publicat: (2004)

High titre vectors for targeted expression of multiple genes
per: Darling, D, et al.
Publicat: (2004)

Comparative analysis of extracellular vesicle isolation methods from human AML bone marrow cells and AML cell lines
per: Jonas B. Lang, et al.
Publicat: (2022-10-01)

Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumors.
per: Gaken, J, et al.
Publicat: (1997)

The Metabolic Signature of AML Cells Treated With Homoharringtonine
per: Yulong Zhang, et al.
Publicat: (2022-06-01)

MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML
per: Naidu M. Vegi, et al.
Publicat: (2016-07-01)

Automated and closed clinical-grade manufacturing protocol produces potent NK cells against neuroblastoma cells and AML blasts
per: Farhana Jahan, et al.
Publicat: (2024-11-01)

AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets.
per: Alessandro Gardini, et al.
Publicat: (2008-11-01)

Prospects of immune gene therapy for cancer
per: Hardwick, N, et al.
Publicat: (2004)

MicroRNA-mRNA Pairs Associated with Outcome in AML: From in vitro Cell-based Studies to AML Patients
per: Neha S Bhise, et al.
Publicat: (2016-01-01)

Cytoplasmic NEAT1 Suppresses AML Stem Cell Self‐Renewal and Leukemogenesis through Inactivation of Wnt Signaling
per: Huiwen Yan, et al.
Publicat: (2021-11-01)

An immune edited tumour versus a tumour edited immune system: Prospects for immune therapy of acute myeloid leukaemia.
per: Chan, L, et al.
Publicat: (2006)

Abolishing Retro-Transduction of Producer Cells in Lentiviral Vector Manufacturing
per: Soledad Banos-Mateos, et al.
Publicat: (2024-07-01)

Identification of a small molecule for enhancing lentiviral transduction of T cells
per: Paulina Malach, et al.
Publicat: (2023-12-01)

Biomarkers as targets for CAR-T/NK cell therapy in AML
per: Ruonan Shao, et al.
Publicat: (2023-06-01)

Chimeric antigen receptor T-cell therapy for T-ALL and AML
per: Wenwen Wei, et al.
Publicat: (2022-11-01)

P577: 20% BLAST CRITERIA FOR DIAGNOSING AML/MDS: IS IT TIME TO MOVE BEYOND?
per: V. Sheth, et al.
Publicat: (2022-06-01)

Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients
per: Peter Holicek, et al.
Publicat: (2023-03-01)

8-Hydroxydaidzein Induces Apoptosis and Inhibits AML-Associated Gene Expression in U-937 Cells: Potential Phytochemical for AML Treatment
per: Pei-Shan Wu, et al.
Publicat: (2023-10-01)

Alteration of T cell immunity by lentiviral transduction of human monocyte-derived dendritic cells
per: Chang Lung-Ji, et al.
Publicat: (2004-11-01)

P1309: DYSREGULATED EXPRESSIONS OF INHIBITORY CHECKPOINT MOLECULES AND THEIR LIGANDS ON T-CELLS AND BLASTS IN AML RELAPSES AFTER STEM CELL TRANSPLANTATION (SCT)
per: S. Bohlscheid, et al.
Publicat: (2022-06-01)

P1350: M2-LIKE MONOCYTE-DERIVED MACROPHAGES PROTECT AML CELL LINES AND PRIMARY AML CELLS AGAINST THERAPY-INDUCED APOPTOSIS
per: Katerina Miari, et al.
Publicat: (2023-08-01)

THE CHALLENGE OF AML IN OLDER PATIENTS
per: Alan K Burnett
Publicat: (2013-06-01)

The Evolving Treatment Landscape of AML
per: Sabine Blum, et al.
Publicat: (2022-03-01)

Maintenance of telomere length in AML
per: Peter M. Lansdorp
Publicat: (2017-11-01)

Inherited predisposition to MDS/AML
per: Ana Rio Machin, et al.
Publicat: (2018-06-01)

The Evolving Treatment Landscape of AML
per: Sabine Blum, et al.
Publicat: (2022-03-01)

Emerging agents and regimens for AML
per: Hongtao Liu
Publicat: (2021-03-01)

TARGETED THERAPY IN AML TREATMENT
per: Giovanni Martinelli
Publicat: (2021-11-01)

ELMO1 is upregulated in AML CD34+ stem/progenitor cells, mediates chemotaxis and predicts poor prognosis in normal karyotype AML.
per: Marta E Capala, et al.
Publicat: (2014-01-01)